Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening

Yang, Wei; Padkjær, Søren Berg; Wang, Jishu; Sun, Zhe; Shan, Bing; Li, Yang; Chen, Haibin; Kang, Lishan; Madsen, Dennis; Li, Xun; Shen, Chenxi; Yu, Bingke; Zhu, Haisun; Chao, Tzu‐Yuan; Cao, Zhixing; Li, Dapeng; Liu, Wei; Du, Yanping; Xǔ, Jǐnjīng; Hao, Dongxia; Xu, Fengting; Peng, Lujia; Li, Tengkun; Wang, Lin; Li, Lin; Xing, Haimei; Liu, Di; Liu, Zibing; Guan, Zhishuang; Wang, Wan; Cheng, Hong; Østergaard, Henrik; Chang, Chen-Kang; Yang, Zhiru; Boel, Esper; Su, Jing

doi:10.1016/j.jbiotec.2017.08.023

Cited by 22 publications

(33 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this work was in progress, Yang et al . identified binding of VSIG‐3 to VISTA by SPR and reported a K d value in the μ m range . We have repeated the experiment by Yang et al .…”

Section: Discussionmentioning

confidence: 69%

“…Recently, regulation of excitatory synaptic transmission and plasticity functions was suggested for VSIG‐3 through its interactions with the postsynaptic scaffolding protein PSD‐95 and AMPARs. Lately VSIG‐3 as a new binding partner for VISTA was identified using a cell surface displayed library, and confirmed by both fluorescence‐activated cell sorting and SPR assays . However, the biological significance of VSIG‐3 and VISTA interaction is still unknown.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

VSIG‐3 as a ligand of VISTA inhibits human T‐cell function

et al. 2018

View full text Add to dashboard Cite

B7 family members and their receptors play a central role in the regulation of T-cell responses through T-cell co-stimulation and co-inhibition pathways that constitute attractive targets for the development of immunotherapeutic drugs. In this study, we report that VSIG-3/IGSF11 is a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. An extensive functional ELISA binding screening assay reveals that VSIG-3 binds to the new B7 family member VISTA but does not interact with other known members of the B7 family. Under the same experimental conditions, we did not observe any significant interaction between VSIG-8 and VISTA. In addition, VSIG-3 inhibits human T-cell proliferation in the presence of T-cell receptor signaling. Furthermore, VSIG-3 significantly reduces cytokine and chemokine production by human T cells including IFN-γ, IL-2, IL-17, CCL5/Rantes, CCL3/MIP-1α, and CXCL11/I-TAC. Anti-VISTA neutralization antibodies attenuate the binding of VSIG-3 and VISTA, as well as VSIG-3-induced T-cell inhibition. Hence, we have identified a novel ligand for VISTA that is able to inhibit human T-cell proliferation and cytokine production. This unique VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may aid in the design of better vaccines.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

VSIG‐3 as a ligand of VISTA inhibits human T‐cell function

et al. 2018

View full text Add to dashboard Cite

show abstract

“…18 In the testis, IgSF11 has been demonstrated to be expressed in Sertoli cells and to maintain a functional blood-testis barrier. 19 Recently, IgSF11 has been identified as a ligand of the B7 family member V-domain Ig suppressor of T-cell activation (VISTA, also known as PD-1H), 20 which has been revealed to have inhibitory effects on human T cell function. 21 IgSF11 has also been characterized as a gene frequently upregulated in intestinal type gastric cancers.…”

Section: Introductionmentioning

confidence: 99%

IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95

et al. 2020

View full text Add to dashboard Cite

Osteoclasts are multinucleated, giant cells derived from myeloid progenitors. While receptor activator of NF-κB ligand (RANKL) stimulation is the primary driver of osteoclast differentiation, additional signaling further contributes to osteoclast maturation. Here, we demonstrate that immunoglobulin superfamily member 11 (IgSF11), whose expression increases during osteoclast differentiation, regulates osteoclast differentiation through interaction with postsynaptic density protein 95 (PSD-95), a scaffold protein with multiple protein interaction domains. IgSF11 deficiency in vivo results in impaired osteoclast differentiation and bone resorption but no observed defect in bone formation. Consequently, IgSF11-deficient mice exhibit increased bone mass. Using in vitro osteoclast culture systems, we show that IgSF11 functions through homophilic interactions. Additionally, we demonstrate that impaired osteoclast differentiation in IgSF11-deficient cells is rescued by full-length IgSF11 and that the IgSF11-PSD-95 interaction requires the 75 C-terminal amino acids of IgSF11. Our findings reveal a critical role for IgSF11 during osteoclast differentiation and suggest a role for IgSF11 in a receptor-and signal transduction molecule-containing protein complex.Bone Research (2020) 8:5; https://doi.

show abstract

“…Thus, it seems apparent that VISTA functions as a checkpoint ligand through a putative counterreceptor expressed on T cells which has yet-to-be identified (27). More recently, a high-throughput screening using a single-pass transmembrane protein library has identified IGSF11 (also known as VSIG3) as a VISTA-binding partner (28). Experimentally, we have since confirmed that recombinant human IGSF11 does bind to recombinant human VISTA.COMP (K D = 0.024 µM) and VISTA-Fc (K D = 1.3 µM) using surface plasmon resonance binding assays (data not shown).…”

Section: Discussionmentioning

confidence: 99%

“…Experimentally, we have since confirmed that recombinant human IGSF11 does bind to recombinant human VISTA.COMP (K D = 0.024 µM) and VISTA-Fc (K D = 1.3 µM) using surface plasmon resonance binding assays (data not shown). Interestingly, IGSF11 is predominantly expressed in the brain and sex organs, and the physiological relevance of the VISTA-IGSF11 interaction is not yet understood (28). Current research is ongoing to determine if IGSF11 is expressed by myeloid, lymphoid, or cancer cells, with a view to characterize if an immunological role for this molecule exists.…”

Section: Discussionmentioning

confidence: 99%